Literature DB >> 15466660

Cyclophilin A functions as an endogenous inhibitor for membrane-bound guanylate cyclase-A.

Zi-Jiang Chen1, Michael Vetter, Geen-Dong Chang, Shiguo Liu, Danian Che, Yaxian Ding, Sung Soo Kim, Chung-Ho Chang.   

Abstract

Cyclophilin A (CypA), a receptor for the immunosuppressive agent cyclosporin A, is a cis-trans-peptidyl-prolyl isomerase (PPIase). It accelerates the cis-trans isomerization of prolyl-peptide bonds. CypA binds and regulates the activity of a variety of proteins. Atrial natriuretic factor (ANF) and its receptor membrane-bound guanylate cyclase-A (GC-A) are involved in the regulation of blood pressure. We examined whether CypA affects the activation of GC-A by ANF. The results showed that CypA associated with GC-A. Interestingly, binding of ANF to GC-A released CypA. Transfection of CypA inhibited ANF-stimulated GC-A activity, indicating that CypA functions as an endogenous inhibitor for GC-A activation. CypA also inhibits the activity of guanylate cyclase-C (GC-c), the catalytic domain of GC-A, indicating that CypA interacts with the catalytic domain of GC-A. In contrast, transfection of CypA R55A, a CypA mutant expressing low PPIase activity, did not significantly attenuate the activity of GC-c and the activation of GC-A. Inhibition of PPIase activity of CypA with cyclosporin A also blocks the inhibitory effect of CypA on GC-c activity. These results demonstrate that PPIase activity is required for CypA to inhibit GC-c activity and GC-A activation by ANF. Furthermore, mutation of Pro 822, 902, or 958 in GC-c abolished its activity. Therefore, it is likely that CypA binds to GC-A and catalyzes the cis-trans isomerization of Pro 822, 902, or 958, which keeps GC-A in the inactive state, and that binding of ANF to GC-A alters the conformation of the catalytic domain that releases CypA from GC-A leading to enzyme activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466660     DOI: 10.1161/01.HYP.0000145859.94894.23

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Melatonin attenuates angiotensin II-induced cardiomyocyte hypertrophy through the CyPA/CD147 signaling pathway.

Authors:  Hongyan Su; Jingyuan Li; Tongshuai Chen; Na Li; Jie Xiao; Shujian Wang; Xiaobin Guo; Yi Yang; Peili Bu
Journal:  Mol Cell Biochem       Date:  2016-09-02       Impact factor: 3.396

2.  Development of an AT2-deficient proximal tubule cell line for transport studies.

Authors:  Philip G Woost; Robert J Kolb; Chung-Ho Chang; Margaret Finesilver; Tadashi Inagami; Ulrich Hopfer
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-10-26       Impact factor: 2.416

3.  Functions of cyclophilin A in atherosclerosis.

Authors:  Zhang Tian-Tian; Zhang Jun-Feng; Ge Heng
Journal:  Exp Clin Cardiol       Date:  2013

4.  Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target.

Authors:  Koichi Watashi; Kunitada Shimotohno
Journal:  Drug Target Insights       Date:  2007-02-05

5.  Elevation of soluble guanylate cyclase suppresses proliferation and survival of human breast cancer cells.

Authors:  Hui-Chin Wen; Chih-Pin Chuu; Chen-Yu Chen; Shine-Gwo Shiah; Hsing-Jien Kung; Kuang-Liang King; Liang-Chen Su; Shi-Chuan Chang; Chung-Ho Chang
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

6.  Activation of Akt by advanced glycation end products (AGEs): involvement of IGF-1 receptor and caveolin-1.

Authors:  Su-Jung Yang; Chen-Yu Chen; Geen-Dong Chang; Hui-Chin Wen; Ching-Yu Chen; Shi-Chuan Chang; Jyh-Fei Liao; Chung-Ho Chang
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

7.  Hyperglycemia and advanced glycation end products (AGEs) suppress the differentiation of 3T3-L1 preadipocytes.

Authors:  Chia-Chu Chang; Chen-Yu Chen; Geen-Dong Chang; Ting-Huan Chen; Woan-Ling Chen; Hui-Chin Wen; Chih-Yang Huang; Chung-Ho Chang
Journal:  Oncotarget       Date:  2017-07-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.